Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm
NCT07336771
JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
A Multicenter, Open-Label, Phase Ib/II Randomized Study of JSKN016 in Combination With D-0502 in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Interventions
D-0502 JSKN016 Q2W JSKN016 Q3W
Updated 1 time since 2026 Last updated: Jan 4, 2026 Started: Jan 31, 2026 Primary completion: Dec 31, 2027 Completion: Jun 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1/PHASE2 clinical study on Locally Advanced Breast Cancer (LABC) and Metastatic Breast Cancer, this trial is actively recruiting participants. The trial is conducted by Jiangsu Alphamab Biopharmaceuticals Co., Ltd and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Data source: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .